Once-daily , subcutaneous liraglutide ( 3.0 mg ) ( n = 423 ) , liraglutide ( 1.8 mg ) ( n = 211 ) , or placebo ( n = 212 ) , all as adjunct to 500 kcal/d dietary deficit and increased physical activity ( 150 min/wk ) .